Tag: Psoriasis
ABP 501, Adalimumab Biosimilar, Safe and Effective, for Psoriasis
Findings based on comparison over 52 weeks, including single transition
Tofacitinib Associated With Improvement in Nail Psoriasis
Improvement in nail psoriasis severity at 16 weeks versus placebo; maintained through 52 weeks
Ixekizumab Improves Symptoms in Patients With Psoriatic Arthritis
Two-week and four-week ixekizumab dosing regimens improved signs and symptoms
Uveitis Risk Higher Among Individuals With Psoriasis
Increased risk with severe psoriasis, mild psoriasis with psoriatic arthritis
Specific Factors Influence First-Line Biologic Rx for Psoriasis
Presence of psoriatic arthritis, weight, employment status, baseline disease severity all affect selection
Lower Psoriasis Area, Severity Scores for Women Versus Men
No differences in medication use before enrollment could explain these gender differences
Psoriasis May Up Risk of Melanoma, Hematologic Cancer
No differences in risk observed for type of psoriasis therapy, including systemic or biologic medications
Musculoskeletal Symptoms Predict Psoriatic Arthritis
Joint pain, fatigue, stiffness, worsening of physical function all predict PsA in patients with psoriasis
Depressed Psoriasis Patients at Higher Risk of Psoriatic Arthritis
Risk of psoriatic arthritis up 37 percent for psoriasis patients with depression
FDA Approves Siliq for Plaque Psoriasis
Injected medication approved for use by patients who've failed other treatments
